Allison Dorval was appointed as a director of Puma Biotechnology, effective July 15, 2021. Ms. Dorval served as Chief Financial Officer for Verve Therapeutics, Inc., a public biotechnology company, from November 2021 to August 2025, when Verve was acquired by Eli Lilly. Ms. Dorval previously served as Chief Financial Officer of Voyager Therapeutics, Inc., a public clinical stage gene therapy company, from November 2018 to November 2021, and as Voyager’s principal financial officer and principal accounting officer since June 2018. Ms. Dorval joined Voyager as its Vice President of Finance in June 2017.
Prior to joining Voyager, Ms. Dorval served as Vice President and Controller of Juniper Pharmaceuticals, Inc., a biopharmaceutical company, from August 2016 to June 2017, and as a consultant at Danforth Advisors, a life sciences consultancy focusing on accounting and financial matters, from September 2015 to August 2016. In connection with her role at Danforth, Ms. Dorval served as interim Chief Financial Officer of medical device companies 480 Biomedical, Inc. and Arsenal Medical, Inc. from December 2015 to August 2016. Previously, Ms. Dorval served in several roles at Insulet Corporation, a medical device company, from August 2008 to July 2015, including as Chief Financial Officer from November 2014 to May 2015 and as Vice President and Controller from August 2008 to November 2014. Earlier in her career, Ms. Dorval served in various financial and accounting capacities at iBasis, Inc., a telecommunications company; Digitas Inc., an advertising company; and PricewaterhouseCoopers LLP.
Ms. Dorval received a B.S. in Business Administration, with a concentration in Accounting, from the University of Vermont and has completed a graduate-level certificate program in Taxation at Bentley University’s McCallum Graduate School of Business. She is a certified public accountant. Ms. Dorval was selected as a director because of her extensive background in finance and accounting and her significant experience in the life sciences industry.
What is Allison Dorval's net worth?
The estimated net worth of Allison Dorval is at least $568.44 thousand as of June 13th, 2025. Dorval owns 75,390 shares of Puma Biotechnology stock worth more than $568,441 as of April 28th. This net worth approximation does not reflect any other assets that Dorval may own. Learn More about Allison Dorval's net worth.
How do I contact Allison Dorval?
Has Allison Dorval been buying or selling shares of Puma Biotechnology?
Allison Dorval has not been actively trading shares of Puma Biotechnology during the last quarter. Most recently, Allison Dorval sold 11,610 shares of the business's stock in a transaction on Friday, June 13th. The shares were sold at an average price of $3.40, for a transaction totalling $39,474.00. Following the completion of the sale, the director now directly owns 75,390 shares of the company's stock, valued at $256,326. Learn More on Allison Dorval's trading history.
Who are Puma Biotechnology's active insiders?
Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Alessandra Cesano (Director), Allison Dorval (Director), Douglas Hunt (Insider), Jeffrey Ludwig (Insider), Ann Miller (Director), Jay Moyes (Director), Maximo Nougues (CFO), Adrian Senderowicz (Director), Brian Stuglik (Director), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.
Are insiders buying or selling shares of Puma Biotechnology?
During the last year, insiders at the biopharmaceutical company sold shares 16 times. They sold a total of 237,586 shares worth more than $951,627.52. The most recent insider tranaction occured on January, 7th when CEO Alan H Auerbach sold 18,012 shares worth more than $105,910.56. Insiders at Puma Biotechnology own 23.3% of the company.
Learn More about insider trades at Puma Biotechnology. Information on this page was last updated on 1/7/2026.
